A biotech company making a jump from the OTC market to the Nasdaq is certainly not as difficult as finding a cure for Alzheimer’s Disease. However, OTC investors are well aware that up-listings are a rare phenomenon.
Neurotrope Inc NTRP 0.51% investors are hoping that the company’s move from the OTC market to the Nasdaq this week is a sign that Neurotrope can beat the odds when it comes to treating Alzheimer’s as well.
“We continue to execute on our clinical and corporate strategy and anticipate announcing top line efficacy results from our randomized, placebo controlled Phase 2 study in 148 moderate to severe Alzheimer’s dementia patients in April 2017,” president and chief scientific officer Daniel Alkon, M.D., said in a press release this week. “We are pleased that we will be able to make that announcement as a NASDAQ listed company.”
Benzinga had the chance to speak with Neurotrope CEO Susanne Wilke, Ph.D., back in January. Wilke discussed the incredible potential the company sees in its Bryostatin drug.
Chatting With Neurotrope’s CEO
Although Neurotrope is still a long way from proving its hypothesis, Wilke told Benzinga that Bryostatin may be able to help Alzheimer’s patients reactivate synaptic networks in their brain that have been lost to dementia.
“We believe that this mechanism is a fundamental mechanism for neurodegenerative diseases in general,” Wilke explained. “We definitely want to go into Fragile X [syndrome], we are thinking about Rett Syndrome. There’s other areas. Obviously, stroke, Parkinson’s, depression may be an area.”
Neurotrope stock is…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
